Nisha Pandey

FDA Approves New Parkinson’s Drug That Targets Dopamine Receptors: All About Tavapadon

The <span>US Food and Drug Administration</span> has approved <span>tavapadon</span>, a once-daily oral medicine for adults with Parkinson’s disease. This has added a new option to Parkinson's treatment strategy that has long relied on drugs that mimic the brain’s dopamine supply. The drug will be sold in the US under the brand name <span>Juvmo</span>. 

Tavapadon is different from traditional dopamine agonists because it selectively targets D1 and D5 dopamine receptors. It has been studied both as an early treatment and alongside levodopa in people with more advanced Parkinson’s disease and motor fluctuations. 

<h2>Parkinson’s Disease &amp; Dopamine </h2>

<a href="https://www.healthandme.com/health-wellness/memory-issues-in-dementia-parkinsons-patients-linked-to-natural-mouth-gut-bacteria-article-151945350" data-type="tilCustomLink">Parkinson’s disease</a> is a progressive neurological disorder in which dopamine-producing nerve cells in a region of the brain called the substantia nigra disappear gradually. 

Dopamine is essential for controlling movement. As its levels fall, people can develop symptoms like tremor, stiffness, slowness of movement and problems with balance. 

This is why many Parkinson’s treatments entail increasing dopamine levels or mimicking its effects in the brain. 

Also read: <a href="https://www.healthandme.com/health-news/parkinsons-is-rising-across-us-but-not-equally-why-are-some-states-seeing-more-cases-than-others-article-156027976" data-type="tilCustomLink">Parkinson’s Is Rising Across US, But Not Equally: Why Are Some States Seeing More Cases Than Others?</a>

<a href="https://www.healthandme.com/health-news/what-is-normal-pressure-hydrocephalus-the-brain-disorder-billy-joel-is-diagnosed-with-article-151712318" data-type="tilCustomLink">Tavapadon</a> is a selective D1/D5 partial dopamine agonist. It means that it does not simply increase the amount of dopamine in the brain. Instead, it binds to particular dopamine receptors and partially activates them, essentially helping reproduce some of dopamine’s signalling effects. 

Most currently available dopamine agonists target D2/D3 receptors. Tavapadon’s D1/D5 is therefore one of its distinguishing characteristics. Researchers have been investigating whether this drug can can help provide motor symptom relief while avoiding some adverse effects linked with dopamine receptor activation.

The FDA’s approval was supported by the phase 3 TEMPO clinical programme. In TEMPO-1, which involved 529 people with early Parkinson’s disease, both 5 mg and 15 mg daily doses of tavapadon significantly improved motor function compared to placebo after 26 weeks. 

The drug has also been studied in people already taking levodopa who experience motor fluctuations, a common problem with progressive Parkinson’s. In the TEMPO-3 trial involving 507 participants, adding tavapadon to levodopa increased daily 'on' time without troublesome <span>dyskinesia</span> compared to placebo.

As Parkinson’s disease progresses, some people taking levodopa experience periods when the medicine is working well and movement improves. This is called 'on' time. When the medication’s effect wears off and <a href="https://www.healthandme.com/health-wellness/body-tremors-and-spontaneous-parkinsons-linked-to-this-type-of-dementia-article-152128385" data-type="tilCustomLink">Parkinson’s symptoms</a> return, it is called 'off' time. 

Treatment aims to increase 'on' time while limiting troublesome involuntary movements, known as dyskinesia.

Alzheimer’s Disease: Early Signs, Symptoms, Diagnosis & Prevention Tips

Tavapadon was generally tolerated in the clinical trials, but it is not free of side effects. In the TEMPO-1 trial, the most commonly reported adverse events were: 

<ul><li>Nausea</li><li>Headache</li><li>Dizziness</li></ul>

The FDA’s approval follows data showing improvement in Parkinson’s symptoms, but longer-term safety remains an important factor that needs more investigation. 

<a href="https://www.healthandme.com/health-wellness/world-parkinsons-day-these-5-supplements-can-help-in-managing-this-neurological-condition-article-151394270" data-type="tilCustomLink">Dopamine agonists</a> can also be associated with sleepiness, low blood pressure on standing, hallucinations and impulse-control disorders. These issues remain relevant when doctors consider where tavapadon fits into an individual’s treatment plan.

Tavapadon treats the symptoms of Parkinson’s disease. It does not restore the dopamine-producing nerve cells that have been lost or stop the neurodegenerative process.

Health Conditions A-Z

health

fda-approves-new-parkinsons-drug-that-targets-dopamine-receptors-all-about-tavapadon

parkinsons

parkinsons disease & dopamine parkinsons

tavapadon

us food and drug administration

juvmo

dyskinesia

parkinsons disease

parkinsons symptoms

inflammation-may-be-quietly-changing-your-heart-study-finds-43-higher-risk-of-heart-attack-stroke

Inflammation May Be Quietly Changing Your Heart: Study Finds 43% Higher Risk Of Heart Attack & Stroke

sudden-floaters-flashes-or-blurred-vision-when-should-you-seek-emergency-care-for-retinal-changes

Sudden Floaters, Flashes Or Blurred Vision? When Should You Seek Emergency Care For Retinal Changes

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

The US Food and Drug Administration has approved tavapadon, a once-daily oral medicine for adults with Parkinson’s disease. This has added a new option to Parkinson's treatment strategy that has long relied on drugs that mimic the brain’s dopamine supply. The drug will be sold in the US under the brand name Juvmo. Tavapadon is different from traditional dopamine agonists because it selectively targets D1 and D5 dopamine receptors. It has been studied both as an early treatment and alongside levodopa in people with more advanced Parkinson’s disease and motor fluctuations. Parkinson’s Disease & Dopamine Parkinson’s disease is a progressive neurological disorder in which dopamine-producing nerve cells in a region of the brain called the substantia nigra disappear gradually. Dopamine is essential for controlling movement. As its levels fall, people can develop symptoms like tremor, stiffness, slowness of movement and problems with balance. This is why many Parkinson’s treatments entail increasing dopamine levels or mimicking its effects in the brain. How Does Tavapadon Work? Also read: Parkinson’s Is Rising Across US, But Not Equally: Why Are Some States Seeing More Cases Than Others?Tavapadon is a selective D1/D5 partial dopamine agonist. It means that it does not simply increase the amount of dopamine in the brain. Instead, it binds to particular dopamine receptors and partially activates them, essentially helping reproduce some of dopamine’s signalling effects. Most currently available dopamine agonists target D2/D3 receptors. Tavapadon’s D1/D5 is therefore one of its distinguishing characteristics. Researchers have been investigating whether this drug can can help provide motor symptom relief while avoiding some adverse effects linked with dopamine receptor activation.The FDA’s approval was supported by the phase 3 TEMPO clinical programme. In TEMPO-1, which involved 529 people with early Parkinson’s disease, both 5 mg and 15 mg daily doses of tavapadon significantly improved motor function compared to placebo after 26 weeks. The drug has also been studied in people already taking levodopa who experience motor fluctuations, a common problem with progressive Parkinson’s. In the TEMPO-3 trial involving 507 participants, adding tavapadon to levodopa increased daily 'on' time without troublesome dyskinesia compared to placebo.As Parkinson’s disease progresses, some people taking levodopa experience periods when the medicine is working well and movement improves. This is called 'on' time. When the medication’s effect wears off and Parkinson’s symptoms return, it is called 'off' time. Treatment aims to increase 'on' time while limiting troublesome involuntary movements, known as dyskinesia.                Side Effects Of Tavapadon? Tavapadon was generally tolerated in the clinical trials, but it is not free of side effects. In the TEMPO-1 trial, the most commonly reported adverse events were: NauseaHeadacheDizzinessThe FDA’s approval follows data showing improvement in Parkinson’s symptoms, but longer-term safety remains an important factor that needs more investigation. Dopamine agonists can also be associated with sleepiness, low blood pressure on standing, hallucinations and impulse-control disorders. These issues remain relevant when doctors consider where tavapadon fits into an individual’s treatment plan.Tavapadon treats the symptoms of Parkinson’s disease. It does not restore the dopamine-producing nerve cells that have been lost or stop the neurodegenerative process.

fda approves new parkinson’s drug that targets dopamine receptors: all about tavapadon

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

FDA Approves New Parkinson’s Drug That Targets Dopamine Receptors: All About Tavapadon

WHO Sets 2027 Flu Vaccine Strains; US States Can Now Order Free COVID Shots For Kids

New York Assisted Suicide Law: Nearly 20 People Reportedly Died Since August

Thyroid Medicine Recall Gets US FDA’s Highest Risk Rating: What To Know

Health Conditions A-Z

FDA Approves New Parkinson’s Drug That Targets Dopamine Receptors: All About Tavapadon

Inflammation May Be Quietly Changing Your Heart: Study Finds 43% Higher Risk Of Heart Attack & Stroke

Sudden Floaters, Flashes Or Blurred Vision? When Should You Seek Emergency Care For Retinal Changes